Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

Also called NCT06674460

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 600 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06674460
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06674460. Randomized; quadruple masking; primary purpose treatment. Start 2025-08-01 (actual); primary completion 2027-10-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Acronym
TASTE-SVD
Condition
Cerebral Small Vessel Disease
Intervention (Drug)
Edaravone Dexborneol Sublingual Tablets
Intervention (Drug)
Placebo
Lead sponsor
Peking Union Medical College Hospital (class: other)

Record details

Record id
cardio:ct-nct06674460
Content hash
081b854ddb700f503e0afe6a56343e07fa622eb2c19beb8cf0501990106dcfd1